MAZE as reported
Maze Therapeutics, Inc. reported $2.5M of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.
$2.5M
Revenue, trailing twelve months · to Q2 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$134M
Net Income · +11% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$107M
Free Cash Flow · +0.20% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.47
EPS · −82% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $2.5M | n/a | Q2 2025 · 4 quarters behind |
| Net Income | −$134M | +11% | Q2 2026 |
| EPS | −$2.47 | −82% | Q2 2026 |
| ROE | −34% | n/a | Q2 2026 |
| ROA | −29% | n/a | Q2 2026 |
| Free Cash Flow | −$107M | +0.20% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Maze Therapeutics, Inc. (MAZE) - Revenue & ProfitRevenue & ProfitMaze Therapeutics, Inc. (MAZE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com